Checkpoint-inhibition in ovarian cancer: rising star or just a dream? |
Pietzner, Klaus
(Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum)
Nasser, Sara (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum) Alavi, Sara (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum) Darb-Esfahani, Silvia (Department of Pathology, Charite-University Medicine of Berlin, Campus Mitte) Passler, Mona (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum) Muallem, Mustafa Zelal (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum) Sehouli, Jalid (Department of Gynecology, European Competence Center for Ovarian Cancer (EKZE), Charite-University Medicine of Berlin, Campus Virchow Klinikum) |
1 | Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015;33:4015-22. DOI |
2 | Karre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol 2002;55:221-8. DOI |
3 | Topfer K, Kempe S, Muller N, Schmitz M, Bachmann M, Cartellieri M, et al. Tumor evasion from T cell surveillance. J Biomed Biotechnol 2011;2011:918471. |
4 | Nurieva R, Wang J, Sahoo A. T-cell tolerance in cancer. Immunotherapy 2013;5:513-31. DOI |
5 | Wu P, Wu D, Li L, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS One 2015;10:e0131403. DOI |
6 | Darb-Esfahani S, Kunze CA, Kulbe H, Sehouli J, Wienert S, Lindner J, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 2016;7:1486-99. |
7 | Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28. DOI |
8 | Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-62. DOI |
9 | Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7. DOI |
10 | Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8. DOI |
11 | Infante JR, Braiteh F, Emens LA, Balmanoukian AS, Oaknin A, Wang Y, et al. 871P. Safety, clinical activity and biomarkers of atezolizumab (atezo) in advanced ovarian cancer (OC). Ann Oncol 2016;27:vi296-312. |
12 | Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20. DOI |
13 | Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71. DOI |
14 | Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30. DOI |
15 | Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005;11:6422-30. DOI |
16 | Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Johnson EA, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: interim results from a phase Ib study. J Clin Oncol 2015;33:abstr 5510. |
17 | Lee JM, Dos Santos Zimmer A, Lipkowitz S, Annumziata CM, Ho TW, Chiou VL, et al. Phase I study of the PD-L1 inhibitor, durvalumab (MEDI4736; D) in combination with a PARP inhibitor, olaparib (O) or a VEGFR inhibitor, cediranib (C) in women's cancers (NCT02484404). J Clin Oncol 2016;34:abstr 3015. |
18 | Disis ML, Patel MR, Pant S, Hamilton EP, Lockhart AC, Kelly K. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: safety and clinical activity. J Clin Oncol 2016;34:abstr 5533. |
19 | Oldenburg J, Normann M, Turzer M, Solheim O, Diep LM, Gajdzik B, et al. PD-1 inhibitor treatment of platinum-resistant epithelial ovarian cancer. J Clin Oncol. Forthcoming 2018. |
20 | Konstantinopoulos PA, Waggoner SE, Vidal GA, Mita MM, Fleming GF, Holloway RW, et al. TOPACIO/Keynote-162 (NCT02657889): a phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC) - results from ROC cohort. J Clin Oncol. Forthcoming 2018. |
21 | Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. DOI |
22 | Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33:3541-3. DOI |
23 | Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20. DOI |
24 | Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15:852-61. DOI |
25 | Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-16. DOI |
![]() |